Advertisement

Reactions Weekly

, Volume 1778, Issue 1, pp 438–438 | Cite as

Tisagenlecleucel

Neurotoxicity and cytokine release syndrome: 7 case reports
Case report
  • 27 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective study of 8 patients [treated between August 2018 and March 2019], 7 patients (4 males and 3 females), aged 17−79 years were described, who developed neurotoxicity (NT) or cytokine release syndrome (CRS) following treatment with tisagenlecleucel for high grade B-cell lymphoma with secondary CNS involvement [dosages and time to reactions onsets; not all outcomes stated].

A 43-year-old woman, with diffuse large B-cell lymphoma, germinal centre B-cell like (DLBCL, GCB), received chimeric antigen receptor (CAR) T-cell course including single IV tisagenlecleucel infusion following administration of lymphodepleting chemotherapy including cyclophosphamide and fludarabine. Additionally, she was receiving concomitant maintenance with ibrutinib. Prior to this therapy,...

Reference

  1. Frigault MJ, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood 134: 860-866, No. 11, 12 Sep 2019. Available from: URL: http://doi.org/10.1182/blood.2019001694 - USA

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations